Sarah Palmer Short

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2206229/publications.pdf

Version: 2024-02-01

23 papers 993

16 h-index 610901 24 g-index

25 all docs

 $\begin{array}{c} 25 \\ \text{docs citations} \end{array}$

25 times ranked

1774 citing authors

#	Article	IF	CITATIONS
1	Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer. Cancer Research, 2011, 71, 603-613.	0.9	140
2	p120-catenin is essential for maintenance of barrier function and intestinal homeostasis in mice. Journal of Clinical Investigation, 2010, 120, 1824-1835.	8.2	119
3	Colorectal Cancer and Metabolism. Current Colorectal Cancer Reports, 2018, 14, 226-241.	0.5	88
4	Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage. Journal of Clinical Investigation, 2015, 125, 2646-2660.	8.2	87
5	Selenoproteins in Tumorigenesis and Cancer Progression. Advances in Cancer Research, 2017, 136, 49-83.	5.0	76
6	Roles for selenium and selenoprotein P in the development, progression, and prevention of intestinal disease. Free Radical Biology and Medicine, 2018, 127, 26-35.	2.9	69
7	RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clinical Cancer Research, 2012, 18, 2184-2198.	7.0	61
8	Selenoproteins and oxidative stress-induced inflammatory tumorigenesis in the gut. Cellular and Molecular Life Sciences, 2017, 74, 607-616.	5.4	57
9	BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis. Gut, 2017, 66, 852-862.	12.1	43
10	Adenoma Formation following Limited Ablation of p120-Catenin in the Mouse Intestine. PLoS ONE, 2011, 6, e19880.	2.5	39
11	Colonic Epithelial-Derived Selenoprotein P Is the Source for Antioxidant-Mediated Protection in Colitis-Associated Cancer. Gastroenterology, 2021, 160, 1694-1708.e3.	1.3	33
12	Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Investigational New Drugs, 2014, 32, 1017-1027.	2.6	27
13	BVES Regulates Intestinal Stem Cell Programs and Intestinal Crypt Viability after Radiation. Stem Cells, 2016, 34, 1626-1636.	3.2	23
14	Kaiso Directs the Transcriptional Corepressor MTG16 to the Kaiso Binding Site in Target Promoters. PLoS ONE, 2012, 7, e51205.	2.5	22
15	p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia. Journal of Clinical Investigation, 2017, 127, 4462-4476.	8.2	19
16	BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability. Mucosal Immunology, 2018, 11, 1363-1374.	6.0	18
17	The transcriptional corepressor MTGR1 regulates intestinal secretory lineage allocation. FASEB Journal, 2015, 29, 786-795.	0.5	13
18	Blood vessel epicardial substance reduces LRP6 receptor and cytoplasmic \hat{l}^2 -catenin levels to modulate Wnt signaling and intestinal homeostasis. Carcinogenesis, 2019, 40, 1086-1098.	2.8	11

#	Article	IF	CITATIONS
19	Using 3D Organoid Cultures to Model Intestinal Physiology and Colorectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 183-191.	0.5	10
20	Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells. Molecular Cancer Research, 2019, 17, 882-894.	3.4	10
21	Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma. Oncogene, 2019, 38, 5091-5106.	5.9	10
22	MTG16 regulates colonic epithelial differentiation, colitis, and tumorigenesis by repressing E protein transcription factors. JCI Insight, 2022, 7, .	5.0	9
23	Selenoprotein P in colitis-associated carcinoma. Molecular and Cellular Oncology, 2016, 3, e1075094.	0.7	8